Bupropion-induced isolated impairment of sensory trigeminal nerve function.
Bupropion is increasingly used for nicotine withdrawal and in the treatment of major depression, especially in bipolar patients. We present the case of a 38-year-old female schizoaffective, rapid-cycling patient treated with bupropion for a depressive episode. After 4 weeks of successful treatment (300 mg/day), the patient developed a circumscribed unilateral impairment of sensory trigeminal nerve function. Symptoms completely recovered after discontinuation of bupropion. When re-exposed to bupropion, mild symptoms reappeared, leading to final discontinuation of bupropion. With this natural on-off-on-off design, a causative role of bupropion for trigeminal impairment in this patient can be assumed. To our knowledge, a similar side-effect of bupropion has not been described to date.
Amann
B
B
Department of Psychiatry, University of Munich, Germany.
Hummel
B
B
Rall-Autenrieth
H
H
Walden
J
J
Grunze
H
H
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D016642:Bupropion / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020433:Trigeminal Nerve Diseases / Q000139:chemically induced* / Q000503:physiopathology
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion